SHANGHAI, Jan. 29, 2024 /PRNewswire/ — Asieris Pharmaceuticals (Stock Code: 688176.SH), a global biopharmaceutical company specializing in discovering, developing, and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced the release of Phase III clinical trial data and real-world study data for APL-1706 (compound name: Hexaminolevulinate Hydrochloride for Intravesical Solution), a bladder cancer diagnosis and management drug , at the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) in the form of a poster presentation (Abstract No. 593).
The study included 158 patients enrolled in a randomized controlled trial (RCT), with 37 patients in the training group and 6 patients randomly assigned to the non-Blue Light Cystoscopy (BLC) group, one patient withdrew. A total of 114 patients were in the full analysis set. Nineteen patients were included in the real-world study (RWS). Among patients diagnosed with Ta, T1, or CIS, 42 out of 97 patients (43.3%) in the RCT and 4 out of 12 patients (33.3%) in the RWS had at least one lesion detected by BLC but not by white light cystoscopy (WLC) (p